{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:29Z","timestamp":1793048789148,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.iac.2018.04.013","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T16:42:49Z","timestamp":1531586569000},"page":"443-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Bone Disease in Mastocytosis"],"prefix":"10.1016","volume":"38","author":[{"given":"Giovanni","family":"Orsolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.iac.2018.04.013_bib4","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"van der Veer","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.013_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","article-title":"Prevalence and risk factors for fragility fracture in systemic mastocytosis","volume":"105","author":"Degboe","year":"2017","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.iac.2018.04.013_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajh.24490","article-title":"Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study","volume":"91","author":"Broesby-Olsen","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD position development conference","volume":"11","author":"Baim","year":"2008","journal-title":"J\u00a0Clin Densitom"},{"issue":"5","key":"10.1016\/j.iac.2018.04.013_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S8756-3282(02)00875-X","article-title":"A\u00a0potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men","volume":"31","author":"Brumsen","year":"2002","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib11","doi-asserted-by":"crossref","first-page":"75.e1-7","DOI":"10.1016\/j.amjmed.2012.07.018","article-title":"Bone complications of mastocytosis: a link between clinical and biological characteristics","volume":"126","author":"Guillaume","year":"2013","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.iac.2018.04.013_bib12","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","article-title":"Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis","volume":"24","author":"Seitz","year":"2013","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jcp.21468","article-title":"Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor","volume":"216","author":"Kanzaki","year":"2008","journal-title":"J\u00a0Cell Physiol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.013_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/cea.12914","article-title":"Assessment of in\u00a0vivo mast cell reactivity in patients with systemic mastocytosis","volume":"47","author":"Gulen","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(199710)173:1<10::AID-JCP2>3.0.CO;2-M","article-title":"H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model","volume":"173","author":"Dobigny","year":"1997","journal-title":"J\u00a0Cell Physiol"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts","volume":"174","author":"Biosse-Duplan","year":"2009","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.iac.2018.04.013_bib22","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1073\/pnas.0934373100","article-title":"Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss","volume":"100","author":"Fitzpatrick","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"279","key":"10.1016\/j.iac.2018.04.013_bib23","first-page":"281","article-title":"Bone mastocytosis. A report of nine cases with a bone histomorphometric study","author":"de Gennes","year":"1992","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"10.1016\/j.iac.2018.04.013_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002920000439","article-title":"Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases","volume":"22","author":"Delling","year":"2001","journal-title":"Pathologe"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2015-07-655100","article-title":"KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression","volume":"127","author":"Garcia-Montero","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.scr.2015.04.005","article-title":"Impaired function of bone marrow stromal cells in systemic mastocytosis","volume":"15","author":"Nemeth","year":"2015","journal-title":"Stem Cell Res"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40291-017-0272-1","article-title":"The utility of biomarkers in osteoporosis management","volume":"21","author":"Garnero","year":"2017","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00223-016-0198-3","article-title":"Longitudinal evaluation of bone mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis","volume":"100","author":"Artuso","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cea.12627","article-title":"Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis","volume":"46","author":"Bulai Livideanu","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000091172","article-title":"Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis","volume":"139","author":"Kushnir-Sukhov","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.013_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","article-title":"The role of mast cells in osteoporosis","volume":"36","author":"Chiappetta","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.iac.2018.04.013_bib33","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Pt 7","key":"10.1016\/j.iac.2018.04.013_bib34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in\u00a0vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"J\u00a0Cell Sci"},{"issue":"5","key":"10.1016\/j.iac.2018.04.013_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00223-015-9969-5","article-title":"Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis","volume":"96","author":"Rossini","year":"2015","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.12.007","article-title":"Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"133","author":"Rossini","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.013_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ajh.24382","article-title":"Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients","volume":"91","author":"Pieri","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.013_bib38","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients' perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.iac.2018.04.013_bib39","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2018.04.013_bib40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.iac.2018.04.013_bib41","first-page":"1471","article-title":"A\u00a0retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis","volume":"35","author":"Chen","year":"1994","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.iac.2018.04.013_bib42","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/ccr3.1232","article-title":"Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis","volume":"5","author":"Bonifacio","year":"2017","journal-title":"Clin Case Rep"},{"issue":"11","key":"10.1016\/j.iac.2018.04.013_bib43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.5650051104","article-title":"Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes","volume":"5","author":"Graves","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1359\/jbmr.2002.17.4.567","article-title":"Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy","volume":"17","author":"Brumsen","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.iac.2018.04.013_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"11","key":"10.1016\/j.iac.2018.04.013_bib47","doi-asserted-by":"crossref","first-page":"1127.e1-4","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.iac.2018.04.013_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"10.1016\/j.iac.2018.04.013_bib49","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/jbmr.49","article-title":"The role of mast cells in parathyroid bone disease","volume":"25","author":"Turner","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.iac.2018.04.013_bib50","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","article-title":"Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b","volume":"72","author":"Weide","year":"1996","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.iac.2018.04.013_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002770050604","article-title":"IFNalpha treatment in systemic mastocytosis","volume":"78","author":"Lehmann","year":"1999","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.013_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.013_bib54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis","volume":"26","author":"Laroche","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.iac.2018.04.013_bib55","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.iac.2018.04.013_bib56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.04.013_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.iac.2018.04.013_bib58","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2016-01-690669","article-title":"Resolution of osteosclerosis after alloHCT in systemic mastocytosis","volume":"127","author":"Ustun","year":"2016","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T16:42:56Z","timestamp":1531586576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118300419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0889856118300419"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.013","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Disease in Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}